Sign In
Buy AGTC
$0.397
+0 (+0%)
At Close: Feb 28, 2023
Atreca (BCEL) Receives a Rating Update from a Top Analyst - Markets
10:14am, Tuesday, 16'th Jun 2020
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Atreca (BCEL – Research Report),
H.C. Wainwright Reaffirms Their Hold Rating on PDS Biotechnology (PDSB) - Markets
03:47pm, Monday, 15'th Jun 2020
H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB – Research Report) today. The company’s shares
AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials
11:00am, Monday, 15'th Jun 2020
Mobile vision testing unit enables X-linked retinitis pigmentosa and achromatopsia clinical trial patients to maintain important scheduled study assessments during COVID-19.
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Global Blood Therapeutics (GBT –
H.C. Wainwright Thinks Onconova Therapeutics' Stock is Going to Recover - Markets
10:18am, Monday, 15'th Jun 2020
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Onconova Therapeutics (ONTX – Research
New gene therapy technique shows promise in stem cell model of retinitis pigmentosa
05:02pm, Thursday, 11'th Jun 2020
Scientists at Trinity College Dublin and University College London “mini retinas” with mutations in the RP2 gene that cause some forms of retinitis pigmentosa. Delivering a functional RP2 gene to
Atreca (BCEL) Gets a Buy Rating from H.C. Wainwright - Markets
03:45pm, Wednesday, 10'th Jun 2020
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Atreca (BCEL – Research Report),
Is Applied Genetic Technologies (AGTC) Stock Outpacing Its Medical Peers This Year?
03:30pm, Wednesday, 10'th Jun 2020
Is (AGTC) Outperforming Other Medical Stocks This Year?
Why Applied Genetic Technologies (AGTC) Stock Might be a Great Pick
02:50pm, Tuesday, 26'th May 2020
The Applied Genetic Technologies (AGTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Genetic Technologies Announces Pricing of $8.0 Million Public Offering
02:22pm, Tuesday, 26'th May 2020
MELBOURNE, Australia, May 26, 2020 (GLOBE NEWSWIRE via COMTEX) --
MELBOURNE, Australia, May 26, 2020 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:...
Applied Genetic Technologies (AGTC) Upgraded to Strong Buy: Here's What You Should Know
04:00pm, Monday, 25'th May 2020
Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Is Applied Genetic Technologies (AGTC) Outperforming Other Medical Stocks This Year?
03:30pm, Monday, 25'th May 2020
Is (AGTC) Outperforming Other Medical Stocks This Year?
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today
